Spyre Therapeutics (SYRE) Accumulated Expenses: 2015-2025
Historic Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $23.8 million.
- Spyre Therapeutics' Accumulated Expenses rose 81.15% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 81.15%. This contributed to the annual value of $27.7 million for FY2024, which is 111.41% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Accumulated Expenses is $23.8 million, which was up 22.72% from $19.4 million recorded in Q2 2025.
- Spyre Therapeutics' Accumulated Expenses' 5-year high stood at $28.4 million during Q2 2023, with a 5-year trough of $5.7 million in Q2 2024.
- For the 3-year period, Spyre Therapeutics' Accumulated Expenses averaged around $18.2 million, with its median value being $19.4 million (2025).
- Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 80.01% in 2024, then surged by 241.65% in 2025.
- Quarterly analysis of 5 years shows Spyre Therapeutics' Accumulated Expenses stood at $14.0 million in 2021, then dropped by 8.50% to $12.8 million in 2022, then rose by 2.11% to $13.1 million in 2023, then skyrocketed by 111.41% to $27.7 million in 2024, then skyrocketed by 81.15% to $23.8 million in 2025.
- Its Accumulated Expenses stands at $23.8 million for Q3 2025, versus $19.4 million for Q2 2025 and $21.6 million for Q1 2025.